Maze Therapeutics, Inc. 4

Insider Atul Dandekar sold 6,434 shares of Maze Therapeutics, Inc. common stock in small transactions to cover taxes from RSU vesting.

On September 2 and 3, 2026, Atul Dandekar of Maze Therapeutics, Inc. reported four small open-market sales of common stock totaling 6,434 shares at weighted-average prices between approximately $25.81 and $27.12 per share, reducing his direct holdings from 38,750 to 32,316 shares. The Form 4 footnote clarifies that these dispositions were made solely to cover tax withholding obligations arising from the vesting of restricted stock units, indicating a routine, compensation-related transaction rather than a discretionary reduction in economic exposure.

Filing Facts

CIK

1842295

Ticker

MAZE

Form

4

Source Type

fda

Accession

0002050167-26-000027

Alert Tier

5